In January 2015, President Obama announced the Precision Medicine Initiative, or PMI. The PMI was originally portioned $215 million in the 2016 budget, with the aim to use patient volunteered…
Read More
YouScript has received a fair amount of attention at HIMSS since we first began attending the conference in 2013. Pharmacogenetic testing and precision prescribing are always hot topics that draw…
Read More
The U.S. Department of Veterans Affairs has awarded a Federal Supply Schedule contract to Genelex as a government supplier, which took effect March 15th, 2016. The contract makes pharmacogenetic testing…
Read More
Big thanks to Ranjit who submitted to this challenge with little notice, description is below. Comments from the online community will also be used as judging criteria. So any responses…
Read More
Have you heard of “alert fatigue"? This is the phrase used to describe the de-sensitization to safety alerts that healthcare providers experience when using healthcare technologies. This de-sensitization occurs because…
Read More
Visit Genelex this week at HIMSS16 in Las Vegas and see why we’re in the headlines: HIMSS Honoree explains why you won’t want to miss Genelex at the conference:…
Read More
Dave Garets, Healthcare IT industry analyst I know what you’re thinking: “Garets is mouthing off again. Thank goodness he doesn’t do it more than once a year.” Last year about…
Read More
Pharmacogenomic clinical analytics provider connects to the U.S.’s largest electronic health record system to support the reduction of drug complications, hospitalizations and ED visits Seattle, WA—February 23, 2016 – Genelex…
Read More
On April 7, 2015 we blogged about a young boy who became comatose after receiving tramadol for post-tonsillectomy pain treatment. It was later learned that the boy was a CYP2D6…
Read More
And what does it mean for me? After President Obama announced the Administration’s Precision Medicine Initiative in his January, 2015 State of the Union Address, internet searches for “precision medicine”…
Read More
